In response to unexpected external pressures, Wuxi Apptec (02359, 603259.SH) has chosen a direct and swift course of action, deploying its own capital to make a decisive statement. On the very day it was added to a U.S. Department of Defense list, this leading CXO company promptly released an announcement detailing a plan to repurchase up to 1 billion yuan worth of its A-shares through centralized bidding.

This move from facing external pressure to delivering a firm response not only helped to calm market sentiment with its speed but also communicated management's strong conviction in the company's long-term value and their commitment to defending it.

The details of the plan are telling. With a maximum repurchase price of 156.95 yuan per share and an estimated volume of approximately 6.37 million shares, the strategy reflects a "positive-sum game" approach. The company has clearly stated that all repurchased shares will be used for an employee stock ownership plan.

Benefiting from prior authorization from a shareholders' meeting, the company was able to implement this plan swiftly within regulatory frameworks, demonstrating high operational efficiency to steady the market.

On a deeper level, this action serves to enhance the long-term incentive mechanism, tightly aligning the interests of the core team with those of the company and its shareholders. It skillfully achieves a dual objective: stabilizing short-term market expectations while promoting long-term development.

The confidence behind this substantial and rapid market support measure stems from Wuxi Apptec's consistently robust fundamental performance and strong cash flow. In 2025, the company reported annual revenue of 45.456 billion yuan, with net profit attributable to shareholders soaring 102.65% year-on-year to 19.151 billion yuan. Its full-year adjusted operating cash flow reached a record high of 16.67 billion yuan.

This strong momentum has continued into 2026, with the company posting first-quarter revenue of 12.4 billion yuan, a new high for the period. The backlog of orders for its ongoing business has also climbed to a historical peak of nearly 60 billion yuan.

This powerful ability to generate cash internally and high earnings visibility provide the company with ample confidence to execute a large-scale share buyback while maintaining significant capital expenditures.

In fact, this 1-billion-yuan A-share repurchase is not an isolated event but the latest step in Wuxi Apptec's efforts to build a long-term "value cycle." Since its listing in 2018, the company has returned nearly 25 billion yuan to investors through cash dividends and share buybacks.

Just at the end of May, the company implemented a record-breaking cash dividend exceeding 4.7 billion yuan and simultaneously launched an H-share incentive trust plan with a total value of 2.5 billion Hong Kong dollars.

As the pharmaceutical R&D outsourcing industry enters a critical phase of "K-shaped divergence," Wuxi Apptec is conveying a high degree of certainty to the market through its strategy of confidence-driven, agile market support.

Moving forward, Wuxi Apptec will continue to focus on its core CRDMO strategy. By adhering to a governance model driven by both capital returns and organizational vitality, it aims to build certainty for sustained growth amidst market volatility, further solidifying its leading position as a core global infrastructure for pharmaceutical R&D and creating long-term, cycle-resilient value for investors.